Arca
Skip to content
Tools
Tools

CYP11B1: Cytochrome P450 11B1, mitochondrial

A cytochrome P450 monooxygenase mainly involved in the biosynthesis of adrenal corticoids.

  • Drugs that act on it: 4
  • Approved: 4
  • In phases 1 to 3: 0
  • Sponsors: 3

Who is on it, and how far along

Every drug ChEMBL records acting on CYP11B1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 4

Approved4

  • Osilodrostat
  • Mitotane
  • Metyrapone
  • Levoketoconazole

Phase 30

    Phase 20

      Phase 10

        Sponsors

        Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 3 of 4 act as: Cytochrome P450 11B1 inhibitor; the rest name their own mechanism.
        OsilodrostatApprovedRecordati Rare DiseasesSmall moleculeInhibitor10
        MitotaneBoxed warningApprovedEsteveSmall moleculeInhibitor9
        MetyraponeApprovedEsteveSmall moleculeInhibitorCytochrome P450 11B1, mitochondrial inhibitor6
        LevoketoconazoleBoxed warningApprovedStrongbridgeSmall moleculeInhibitor0

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 21 in all, from ClinicalTrials.gov.
        Osilodrostat for Glycemic Control in Mild Autonomous Cortisol Secretion (MACS) With Difficult-To-Control Type 2 Diabetes - A Randomized, Double-Blind, Placebo-Controlled Phase 2 StudyOsilodrostatPhase 2Not yet recruitingBeckey TrinhNov 6, 2026
        Combination Osilodrostat and Cabergoline in Cushing's DiseaseOsilodrostatPhase 4Enrolling by invitationUniversity of BasrahMay 22, 2026
        Sleep Loss and Circadian Misalignment - Mechanisms of Insulin ResistanceMetyraponePhase 4RecruitingWashington State UniversityMar 27, 2026
        Metyrapone Versus Osilodrostat in Patients With Metabolic Autonomous Cortisol Secretion (MACS)Metyrapone, OsilodrostatPhase 4RecruitingLaikο General Hospital, AthensDec 5, 2025
        Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)OsilodrostatPhase 4RecruitingJohns Hopkins UniversityNov 25, 2025
        Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's SyndromeOsilodrostatPhase 4RecruitingRECORDATI GROUPNov 25, 2025
        Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACSMetyraponePhase 2RecruitingMayo ClinicAug 22, 2025
        Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)OsilodrostatPhase 2RecruitingMayo ClinicAug 5, 2025
        Cemiplimab as Maintenance Treatment for Advanced Adrenocortical CancerMitotanePhase 2RecruitingAzienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaJul 25, 2025
        Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaMitotanePhase 2RecruitingWest China HospitalFeb 17, 2025
        Effect of Metyrapone on Cardiovascular Risk Factors in Patients With Adrenal Incidentalomas and Cushing's SyndromeMetyraponePhase 4RecruitingIRCCS Azienda Ospedaliero-Universitaria di BolognaJan 30, 2025
        Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma DetectionOsilodrostat—Not yet recruitingImperial College LondonNov 22, 2024
        Study of Preoperative Radiation Therapy in Participants With Resectable Recurrent Abdominal Adrenocortical CarcinomaMitotanePhase 1RecruitingNational Cancer Institute (NCI)Jul 5, 2024
        A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid ReplacementOsilodrostat—RecruitingUniversity of MichiganMay 28, 2024
        Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIMitotanePhase 2RecruitingUNICANCERMar 27, 2024
        Metyrapone for Mild Autonomous Cortisol Secretion (MACS)MetyraponePhase 2Active, not recruitingMayo ClinicOct 30, 2023
        Evaluation of the Efficacy of Addition of Progesterone to Standard Chemotherapy in Adrenocortical Carcinoma (ACC)MitotanePhase 2RecruitingAzienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaJun 22, 2023
        Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma.MetyraponePhase 2Active, not recruitingMaria Sklodowska-Curie National Research Institute of OncologyOct 3, 2022
        Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical CarcinomaMitotanePhase 2Active, not recruitingNational Cancer Center, KoreaSep 5, 2021
        Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of RecurrenceMitotanePhase 3RecruitingM.D. Anderson Cancer CenterJul 11, 2018
        Evaluation of Side Effects of MitotaneMitotane—Active, not recruitingUniversity of WuerzburgDec 5, 2007

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        • Congenital adrenal hyperplasia due to 11-beta-hydroxylase deficiency0.84
        • Glucocorticoid-remediable aldosteronism0.69
        • Adrenal gland disorder0.55
        • Adrenal cortex carcinoma0.52
        • ACTH-dependent Cushing syndrome0.49
        • Neoplasm0.39
        • Adrenal gland hyperfunction0.37
        • Adrenal cortex neoplasm0.37
        • ACTH Syndrome, Ectopic0.26

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1908, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P15538, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.